Abstract Breast cancer type 1 susceptibility protein (BRCA1) is antioncogenes in women, who are genetically predisposed to breast cancer. Therefore, development of a reliable method for sensitive and selective detection of BRCA1 with low concentration level is very important. In this research work a novel immunoassay based on signal amplification strategy of multiple polymers to recognition of BRCA1 protein was developed. The engineered immunoassay prepared by poly (dopamine-beta cyclodextrine-Cetyl trimethylammonium bromide doped by silver nanoparticles (P[DA-β-CD/CTAB])-AgNPs) and functionalized mesoporous silica (MCM-41-SO3H) composite fabricated on the glassy carbon electrode with a large surface area which was prepared a new platform to immobilization of primary antibodies and provide excellent conductivity. To further amplify the electrochemical signal, MCM-41-SO3H provides suitable pores volume and functional groups to capture more horseradish peroxidase-labeled antibodies (HPR-Ab2) and enhances the conductivity. The proposed immunoassay displays suitable analytical performance for the monitoring of BRCA1 with a linear range from 0.01565–10 pg/mL (by DPV) and 0.625–20 pg/mL (by SWV) and a low limit of quantification of 0.003 pg/mL. Also, satisfactory results are obtained for the determination of BRCA1 in human plasma samples and MCF-7 cancer cell lysates, indicating the potential of the immunoassay to be applied in clinical analysis.

中文翻译：

---

使用掺杂银纳米粒子的聚（多巴胺-β 环糊精-十六烷基三甲基溴化铵）对乳腺癌 1 型易感蛋白 (BRCA1) 进行超灵敏免疫测定：乳腺癌早期诊断和有效管理的新平台

摘要 乳腺癌 1 型易感蛋白 (BRCA1) 是具有乳腺癌遗传易感性的女性的抗癌基因。因此，开发一种可靠的方法来灵敏、选择性地检测低浓度水平的 BRCA1 是非常重要的。在这项研究工作中，开发了一种基于多种聚合物的信号放大策略来识别 BRCA1 蛋白的新型免疫测定法。由银纳米粒子掺杂的聚（多巴胺-β-环糊精-十六烷基三甲基溴化铵（P[DA-β-CD/CTAB]）-AgNPs）和功能化介孔二氧化硅（MCM-41-SO3H）复合材料制备的工程免疫分析具有大表面积的碳电极，为固定一抗准备了一个新平台，并提供了优异的导电性。为了进一步放大电化学信号，MCM-41-SO3H 提供了合适的孔体积和官能团，以捕获更多辣根过氧化物酶标记的抗体 (HPR-Ab2) 并增强电导率。建议的免疫测定显示出适合监测 BRCA1 的分析性能，线性范围为 0.01565–10 pg/mL（DPV）和 0.625–20 pg/mL（SWV），定量下限为 0.003 pg/mL。此外，测定人血浆样品和 MCF-7 癌细胞裂解物中的 BRCA1 也获得了令人满意的结果，表明免疫测定在临床分析中的应用潜力。建议的免疫测定显示出适合监测 BRCA1 的分析性能，线性范围为 0.01565–10 pg/mL（DPV）和 0.625–20 pg/mL（SWV），定量下限为 0.003 pg/mL。此外，测定人血浆样品和 MCF-7 癌细胞裂解物中的 BRCA1 也获得了令人满意的结果，表明免疫测定在临床分析中的应用潜力。建议的免疫测定显示出适合监测 BRCA1 的分析性能，线性范围为 0.01565–10 pg/mL（DPV）和 0.625–20 pg/mL（SWV），定量下限为 0.003 pg/mL。此外，测定人血浆样品和 MCF-7 癌细胞裂解物中的 BRCA1 也获得了令人满意的结果，表明免疫测定在临床分析中的应用潜力。